Shanghai Junshi Biosciences Co., Ltd.
Simbols: 1877.HK
HKSE
12.6
HKDTirgus cena šodien
-5.6777
P/E koeficients
0.0426
PEG koeficients
27.42B
MRK Cap
- 0.00%
DIV ienesīgums
Shanghai Junshi Biosciences Co., Ltd. (1877-HK) Finanšu pārskati
Bilance
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 3778.1 | 5996.9 | 3504.6 | ||||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 341.5 | ||||||||
balance-sheet.row.net-receivables | 0 | 483.2 | 517.7 | 1834.8 | ||||||||
balance-sheet.row.inventory | 0 | 538.1 | 599 | 484.6 | ||||||||
balance-sheet.row.other-current-assets | 0 | 744.4 | 91.3 | 7.7 | ||||||||
balance-sheet.row.total-current-assets | 0 | 5549.8 | 7204.9 | 5831.7 | ||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 4253.3 | 3572 | 3421.3 | ||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||
balance-sheet.row.intangible-assets | 0 | 134.4 | 110.5 | 51.8 | ||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 134.4 | 110.5 | 51.8 | ||||||||
balance-sheet.row.long-term-investments | 0 | 1133.1 | 1402.8 | 1123.4 | ||||||||
balance-sheet.row.tax-assets | 0 | 103.4 | 228.4 | 88.5 | ||||||||
balance-sheet.row.other-non-current-assets | 0 | 188.4 | 57.6 | 533.9 | ||||||||
balance-sheet.row.total-non-current-assets | 0 | 5812.6 | 5371.4 | 5219 | ||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||
balance-sheet.row.total-assets | 0 | 11362.5 | 12576.3 | 11050.7 | ||||||||
balance-sheet.row.account-payables | 0 | 247.3 | 281.6 | 196.2 | ||||||||
balance-sheet.row.short-term-debt | 0 | 575.3 | 435.4 | 45.1 | ||||||||
balance-sheet.row.tax-payables | 0 | 59.4 | 35.2 | 80.9 | ||||||||
balance-sheet.row.long-term-debt-total | 0 | 1213.2 | 886.2 | 583.1 | ||||||||
Deferred Revenue Non Current | 0 | 181.1 | 121.6 | 118.8 | ||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||
balance-sheet.row.other-current-liab | 0 | 7.5 | 1057.2 | 1775.4 | ||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 1547.1 | 1007.8 | 701.9 | ||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||
balance-sheet.row.capital-lease-obligations | 0 | 53.4 | 90.2 | 127.6 | ||||||||
balance-sheet.row.total-liab | 0 | 4022.3 | 2782 | 2718.5 | ||||||||
balance-sheet.row.preferred-stock | 0 | 0.3 | 68.4 | 0 | ||||||||
balance-sheet.row.common-stock | 0 | 985.7 | 982.9 | 910.8 | ||||||||
balance-sheet.row.retained-earnings | 0 | -9040.8 | -6776.6 | -4388.6 | ||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | -142.1 | -68.4 | 0.2 | ||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 15367.7 | 15295.2 | 11438.5 | ||||||||
balance-sheet.row.total-stockholders-equity | 0 | 7170.8 | 9501.4 | 7960.9 | ||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 11362.5 | 12576.3 | 11050.7 | ||||||||
balance-sheet.row.minority-interest | 0 | 169.4 | 292.8 | 371.3 | ||||||||
balance-sheet.row.total-equity | 0 | 7340.2 | 9794.3 | 8332.2 | ||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | ||||||||
Total Investments | 0 | 1133.1 | 1402.8 | 1464.9 | ||||||||
balance-sheet.row.total-debt | 0 | 1788.6 | 1321.6 | 628.2 | ||||||||
balance-sheet.row.net-debt | 0 | -1989.6 | -4675.4 | -2876.4 |
Naudas plūsmas pārskats
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |||
---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | -2675.2 | -592.6 | -1669.5 | |||||||
cash-flows.row.depreciation-and-amortization | 0 | 293.7 | 262.6 | 151.4 | |||||||
cash-flows.row.deferred-income-tax | 0 | 0 | -173.8 | -5.7 | |||||||
cash-flows.row.stock-based-compensation | 0 | 91.9 | 192.8 | 30.7 | |||||||
cash-flows.row.change-in-working-capital | 0 | 687.2 | -318.8 | -13.1 | |||||||
cash-flows.row.account-receivables | 0 | 1229.7 | -770.6 | -482.2 | |||||||
cash-flows.row.inventory | 0 | -136.4 | -154.8 | -167 | |||||||
cash-flows.row.account-payables | 0 | -1229.7 | 770.6 | 482.2 | |||||||
cash-flows.row.other-working-capital | 0 | 823.6 | -163.9 | 153.9 | |||||||
cash-flows.row.other-non-cash-items | 0 | -172.9 | -12 | 7.3 | |||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | |||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -394 | -886.2 | -592.7 | |||||||
cash-flows.row.acquisitions-net | 0 | -93.8 | -440.1 | 2.9 | |||||||
cash-flows.row.purchases-of-investments | 0 | -8.5 | -1169.6 | -245.2 | |||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 565.3 | 70.1 | |||||||
cash-flows.row.other-investing-activites | 0 | 28.6 | 49.7 | 66.8 | |||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -467.6 | -1881 | -698 | |||||||
cash-flows.row.debt-repayment | 0 | -113.4 | -793.3 | -401.4 | |||||||
cash-flows.row.common-stock-issued | 0 | 3812.3 | 2150.1 | 4846.9 | |||||||
cash-flows.row.common-stock-repurchased | 0 | 19.2 | 16.7 | 43.2 | |||||||
cash-flows.row.dividends-paid | 0 | -19.2 | -16.7 | -43.2 | |||||||
cash-flows.row.other-financing-activites | 0 | 944.2 | 1308.9 | -32 | |||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 4643 | 2665.7 | 4413.5 | |||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 92.3 | -23.2 | -45.8 | |||||||
cash-flows.row.net-change-in-cash | 0 | 2492.3 | 119.6 | 2171 | |||||||
cash-flows.row.cash-at-end-of-period | 0 | 5996.9 | 3504.6 | 3385 | |||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 3504.6 | 3385 | 1214 | |||||||
cash-flows.row.operating-cash-flow | 0 | -1775.3 | -641.9 | -1498.8 | |||||||
cash-flows.row.capital-expenditure | 0 | -394 | -886.2 | -592.7 | |||||||
cash-flows.row.free-cash-flow | 0 | -2169.3 | -1528.1 | -2091.5 |
Peļņas vai zaudējumu aprēķina rinda
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 1502.5 | 1453.5 | 4024.8 | ||||||||
income-statement-row.row.cost-of-revenue | 0 | 667.3 | 526.3 | 1258.2 | ||||||||
income-statement-row.row.gross-profit | 0 | 835.3 | 927.2 | 2766.7 | ||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||
income-statement-row.row.research-development | 0 | - | - | - | ||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||
income-statement-row.row.other-expenses | 0 | -35.8 | -34.2 | -91.9 | ||||||||
income-statement-row.row.operating-expenses | 0 | 3287.3 | 3644.2 | 3359.4 | ||||||||
income-statement-row.row.cost-and-expenses | 0 | 3954.6 | 4170.4 | 4617.5 | ||||||||
income-statement-row.row.interest-income | 0 | 99.4 | 61 | 31 | ||||||||
income-statement-row.row.interest-expense | 0 | 29 | 29.4 | 21.8 | ||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||
income-statement-row.row.total-other-income-expensenet | 0 | -15.7 | -3.6 | 92.7 | ||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||
income-statement-row.row.other-operating-expenses | 0 | -35.8 | -34.2 | -91.9 | ||||||||
income-statement-row.row.total-operating-expenses | 0 | -15.7 | -3.6 | 92.7 | ||||||||
income-statement-row.row.interest-expense | 0 | 29 | 29.4 | 21.8 | ||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 303.2 | 293.7 | 262.6 | ||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | ||||||||
income-statement-row.row.operating-income | 0 | -2476 | -2671.6 | -685.3 | ||||||||
income-statement-row.row.income-before-tax | 0 | -2489.9 | -2675.2 | -592.6 | ||||||||
income-statement-row.row.income-tax-expense | 0 | 44 | -93.1 | 135.5 | ||||||||
income-statement-row.row.net-income | 0 | -2281.6 | -2582.1 | -728.2 |
Biežāk uzdotie jautājumi
Kas ir Shanghai Junshi Biosciences Co., Ltd. (1877.HK) kopējie aktīvi?
Shanghai Junshi Biosciences Co., Ltd. (1877.HK) kopējie aktīvi ir 11362464000.000.
Kādi ir uzņēmuma gada ieņēmumi?
Gada ieņēmumi ir N/A.
Kāda ir uzņēmuma peļņas norma?
Uzņēmuma peļņas norma ir -0.024.
Kāda ir uzņēmuma brīvā naudas plūsma?
Brīvā naudas plūsma ir -2.642.
Kāda ir uzņēmuma neto peļņas norma?
Neto peļņas norma ir -3.152.
Kādi ir uzņēmuma kopējie ieņēmumi?
Kopējie ieņēmumi ir -3.231.
Kāda ir Shanghai Junshi Biosciences Co., Ltd. (1877.HK) tīrā peļņa (tīrie ienākumi)?
Tīrā peļņa (tīrie ienākumi) ir -2281624000.000.
Kāds ir uzņēmuma kopējais parāds?
Kopējais parāds ir 1788567000.000.
Kāds ir pamatdarbības izdevumu skaits?
Darbības izdevumi ir 3287276000.000.
Kāds ir uzņēmuma skaidrās naudas rādītājs?
Uzņēmuma nauda ir 0.000.